Cargando…

How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials

AIMS/HYPOTHESIS: There are two prerequisites for the precision medicine approach to be beneficial for treated individuals. First, there must be treatment heterogeneity; second, in the case of treatment heterogeneity, we need to detect clinical predictors to identify people who would benefit from one...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuss, Oliver, Opitz, Marie Elisabeth, Brandstetter, Lea Verena, Schlesinger, Sabrina, Roden, Michael, Hoyer, Annika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390610/
https://www.ncbi.nlm.nih.gov/pubmed/37338539
http://dx.doi.org/10.1007/s00125-023-05951-2
_version_ 1785082514950324224
author Kuss, Oliver
Opitz, Marie Elisabeth
Brandstetter, Lea Verena
Schlesinger, Sabrina
Roden, Michael
Hoyer, Annika
author_facet Kuss, Oliver
Opitz, Marie Elisabeth
Brandstetter, Lea Verena
Schlesinger, Sabrina
Roden, Michael
Hoyer, Annika
author_sort Kuss, Oliver
collection PubMed
description AIMS/HYPOTHESIS: There are two prerequisites for the precision medicine approach to be beneficial for treated individuals. First, there must be treatment heterogeneity; second, in the case of treatment heterogeneity, we need to detect clinical predictors to identify people who would benefit from one treatment more than from others. There is an established meta-regression approach to assess these two prerequisites that relies on measuring the variability of a clinical outcome after treatment in placebo-controlled randomised trials. Our aim was to apply this approach to the treatment of type 2 diabetes. METHODS: We performed a meta-regression analysis using information from 174 placebo-controlled randomised trials with 178 placebo and 272 verum (i.e. active treatment) arms including 86,940 participants with respect to the variability of glycaemic control as assessed by HbA(1c) after treatment and its potential predictors. RESULTS: The adjusted difference in log(SD) values between the verum and placebo arms was 0.037 (95% CI: 0.004, 0.069). That is, we found a small increase in the variability of HbA(1c) values after treatment in the verum arms. In addition, one potentially relevant predictor for explaining this increase, drug class, was observed, and GLP-1 receptor agonists yielded the largest differences in log(SD) values. CONCLUSIONS/INTERPRETATION: The potential of the precision medicine approach in the treatment of type 2 diabetes is modest at best, at least with regard to an improvement in glycaemic control. Our finding of a larger variability after treatment with GLP-1 receptor agonists in individuals with poor glycaemic control should be replicated and/or validated with other clinical outcomes and with different study designs. FUNDING: The research reported here received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. DATA AVAILABILITY: Two datasets (one for the log[SD] and one for the baseline-corrected log[SD]) to reproduce the analyses from this paper are available on https://zenodo.org/record/7956635. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00125-023-05951-2) contains peer-reviewed but unedited supplementary material.
format Online
Article
Text
id pubmed-10390610
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-103906102023-08-02 How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials Kuss, Oliver Opitz, Marie Elisabeth Brandstetter, Lea Verena Schlesinger, Sabrina Roden, Michael Hoyer, Annika Diabetologia Article AIMS/HYPOTHESIS: There are two prerequisites for the precision medicine approach to be beneficial for treated individuals. First, there must be treatment heterogeneity; second, in the case of treatment heterogeneity, we need to detect clinical predictors to identify people who would benefit from one treatment more than from others. There is an established meta-regression approach to assess these two prerequisites that relies on measuring the variability of a clinical outcome after treatment in placebo-controlled randomised trials. Our aim was to apply this approach to the treatment of type 2 diabetes. METHODS: We performed a meta-regression analysis using information from 174 placebo-controlled randomised trials with 178 placebo and 272 verum (i.e. active treatment) arms including 86,940 participants with respect to the variability of glycaemic control as assessed by HbA(1c) after treatment and its potential predictors. RESULTS: The adjusted difference in log(SD) values between the verum and placebo arms was 0.037 (95% CI: 0.004, 0.069). That is, we found a small increase in the variability of HbA(1c) values after treatment in the verum arms. In addition, one potentially relevant predictor for explaining this increase, drug class, was observed, and GLP-1 receptor agonists yielded the largest differences in log(SD) values. CONCLUSIONS/INTERPRETATION: The potential of the precision medicine approach in the treatment of type 2 diabetes is modest at best, at least with regard to an improvement in glycaemic control. Our finding of a larger variability after treatment with GLP-1 receptor agonists in individuals with poor glycaemic control should be replicated and/or validated with other clinical outcomes and with different study designs. FUNDING: The research reported here received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. DATA AVAILABILITY: Two datasets (one for the log[SD] and one for the baseline-corrected log[SD]) to reproduce the analyses from this paper are available on https://zenodo.org/record/7956635. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00125-023-05951-2) contains peer-reviewed but unedited supplementary material. Springer Berlin Heidelberg 2023-06-20 2023 /pmc/articles/PMC10390610/ /pubmed/37338539 http://dx.doi.org/10.1007/s00125-023-05951-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Kuss, Oliver
Opitz, Marie Elisabeth
Brandstetter, Lea Verena
Schlesinger, Sabrina
Roden, Michael
Hoyer, Annika
How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials
title How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials
title_full How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials
title_fullStr How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials
title_full_unstemmed How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials
title_short How amenable is type 2 diabetes treatment for precision diabetology? A meta-regression of glycaemic control data from 174 randomised trials
title_sort how amenable is type 2 diabetes treatment for precision diabetology? a meta-regression of glycaemic control data from 174 randomised trials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390610/
https://www.ncbi.nlm.nih.gov/pubmed/37338539
http://dx.doi.org/10.1007/s00125-023-05951-2
work_keys_str_mv AT kussoliver howamenableistype2diabetestreatmentforprecisiondiabetologyametaregressionofglycaemiccontroldatafrom174randomisedtrials
AT opitzmarieelisabeth howamenableistype2diabetestreatmentforprecisiondiabetologyametaregressionofglycaemiccontroldatafrom174randomisedtrials
AT brandstetterleaverena howamenableistype2diabetestreatmentforprecisiondiabetologyametaregressionofglycaemiccontroldatafrom174randomisedtrials
AT schlesingersabrina howamenableistype2diabetestreatmentforprecisiondiabetologyametaregressionofglycaemiccontroldatafrom174randomisedtrials
AT rodenmichael howamenableistype2diabetestreatmentforprecisiondiabetologyametaregressionofglycaemiccontroldatafrom174randomisedtrials
AT hoyerannika howamenableistype2diabetestreatmentforprecisiondiabetologyametaregressionofglycaemiccontroldatafrom174randomisedtrials